[Objective] The research aimed to discuss the effects of rosiglitazone and serum on the expressions of PPARα and PPARγ genes in the induced differentiation process of pig preadipocyte.[Method] The pig preadipocyte w...[Objective] The research aimed to discuss the effects of rosiglitazone and serum on the expressions of PPARα and PPARγ genes in the induced differentiation process of pig preadipocyte.[Method] The pig preadipocyte was separated by using the collagenase digestion method.Three kinds of different differentiation culture solutions were used to induce the differentiation of pig preadipocyte.The oil red O staining extraction method was used to contrast the influences of different differentiation culture solutions on the variation of cellular fat content in the differentiation process.Moreover,the variation trends of PPARα and PPARγ expressions in the cellular differentiation process in the different differentiation culture solutions were detected by the real-time quantification PCR.[Result] The cellular fat accumulation was the fastest in MII which contained rosiglitazone and was the slowest in MI which didn＇t contain rosiglitazone.Rosiglitazone could significantly increase the expression of PPARγ gene（P0.01）,but had the certain inhibition effect on the expression of PPARα gene,which wasn＇t significant.The serum had the extremely significant up-regulation effect on the expression of PPARγ gene（P0.01）,but had the extremely significant down-regulation effect on the expression of PPARα gene（P0.01）.[Conclusion] Rosiglitazone could greatly promote the expression of PPARγ gene,which increased the cellular fat deposition.Maybe the activator of PPARγ gene existed in the serum,and the inhibitor of PPARα gene existed simultaneously.展开更多
According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan ...According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.展开更多
基金Supported by Ministry of Science & Technology International Cooper-ation Project(2011DFB30340)the Earmarked Fund for China Agriculture Research System(CARS-36)the Project of Animal Breeding from Sichuan Bureau of Science & Technology(2006-YZGG-15)~~
文摘[Objective] The research aimed to discuss the effects of rosiglitazone and serum on the expressions of PPARα and PPARγ genes in the induced differentiation process of pig preadipocyte.[Method] The pig preadipocyte was separated by using the collagenase digestion method.Three kinds of different differentiation culture solutions were used to induce the differentiation of pig preadipocyte.The oil red O staining extraction method was used to contrast the influences of different differentiation culture solutions on the variation of cellular fat content in the differentiation process.Moreover,the variation trends of PPARα and PPARγ expressions in the cellular differentiation process in the different differentiation culture solutions were detected by the real-time quantification PCR.[Result] The cellular fat accumulation was the fastest in MII which contained rosiglitazone and was the slowest in MI which didn＇t contain rosiglitazone.Rosiglitazone could significantly increase the expression of PPARγ gene（P0.01）,but had the certain inhibition effect on the expression of PPARα gene,which wasn＇t significant.The serum had the extremely significant up-regulation effect on the expression of PPARγ gene（P0.01）,but had the extremely significant down-regulation effect on the expression of PPARα gene（P0.01）.[Conclusion] Rosiglitazone could greatly promote the expression of PPARγ gene,which increased the cellular fat deposition.Maybe the activator of PPARγ gene existed in the serum,and the inhibitor of PPARα gene existed simultaneously.
文摘According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.
